Research & Development

In the rapidly evolving landscape of synthetic biology, the ability to control engineered cells with the same precision we use to adjust a thermostat is becoming a reality. Ivan Kairatov, a biopharma expert with a deep background in research and development, joins us to discuss a groundbreaking

The landscape of vaccinology is undergoing a seismic shift, moving away from the traditional, reactive methods that have defined the industry for decades. At the forefront of this revolution is Ivan Kairatov, a biopharma expert whose career has been dedicated to bridging the gap between

The persistent struggle against KRAS mutations has long been a defining battle in modern oncology, representing a target once thought to be totally unreachable by conventional drug design due to the protein's lack of accessible binding pockets. For decades, clinicians and researchers faced a

The biopharmaceutical industry reached a significant milestone this week as Waypoint Bio secured twenty million dollars in seed funding to accelerate the development of next-generation chimeric antigen receptor T-cell therapies that utilize advanced artificial intelligence models. This investment

In the world of pediatric oncology, the narrative has long been dominated by the battle for survival. With childhood cancer survival rates in the United States and Europe now exceeding 85%, the victory is undeniable, yet it has birthed a new, complex challenge: the long-term health of over a

The silent molecular transformation occurring within the respiratory and oral pathways of e-cigarette users has finally been mapped by researchers, revealing a startling disruption to the human genetic blueprint. This phenomenon, categorized as transcriptomic dysregulation, signifies a widespread